Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.
Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
Men with diabetes may have a higher risk of experiencing chronic lower back pain, say researchers writing in BMJ Open this month.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Late-in-life weight gain or weight loss appears to be associated with an increased risk of dementia, shows a Korean study of 67,219 men and women between 60-79 years old.
A single course of treatment with teplizumab delayed the development of type 1 diabetes in at-risk teens and children, shows a study presented at the American Diabetes Association annual meeting earlier this month.
Patients with type 2 diabetes and kidney disease who received the SGLT2 inhibitor canagliflozin, had a lower risk of kidney failure and cardiovascular events as compared to a placebo group, a new study shows.
Seasons change, but diabetes remains an intriguing year-round challenge. Here's a short quiz on diabetes treatment from Dr. Edward Chao.